onc Videos

Videos

Expert Panel Explores Polycythemia Vera and the Importance of Hematocrit Control

Videos

Increasing Quality of Life Using Survivorship-Focused Care for Patients With Hodgkin and Non-Hodgkin Lymphoma

05/05/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Matthew Matasar, MD, discussed the importance of utilizing survivorship-focused care models and increasing the quality of life of lymphoma...

At the 2023 Great Debates &...

05/05/2023

Oncology

Videos

Recent Advancements in Clinical Development for the Treatment of Myelofibrosis

05/04/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference, New York, John Mascarenhas, MD, discussed recent advancements in clinical developments for the treatment of myeloproliferative neoplasms, specifically myelofibrosis,...

At the 2023 Great Debates &...

05/04/2023

Oncology

Videos

Optimization of Therapies for Older or More Frail Patients With Multiple Myeloma

05/04/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Joshua Richter, MD, discussed the optimization of therapies for older and more frail patients with multiple myeloma.

At the 2023 Great Debates &...

05/04/2023

Oncology

Videos

Second-Line Therapy for Patients With Polycythemia Vera: A Review of Data on Ruxolitinib

05/04/2023

In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...

In the final part of an expert...

05/04/2023

Oncology

Videos

How to Determine When First-Line Therapy for Polycythemia Vera is Failing

05/04/2023

In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.

In part 3 of an expert...

05/04/2023

Oncology

Videos

Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera

05/04/2023

In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.

In part 2 of an expert...

05/04/2023

Oncology

Videos

Clinical Considerations for Oncologists Treating Transgender Patients

05/03/2023

Allison Asante, PA-C, discusses the key points from their presentation at the 2023 SGO Annual Meeting on Women’s Cancer on considerations when treating transgender patients.

Allison Asante, PA-C, discusses...

05/03/2023

Oncology

Videos

Role of CNS Prophylaxis in Aggressive B-Cell Lymphoma Treatment

05/03/2023

Adam Olszewski, MD, debates that CNS prophylaxis has a valuable role in the treatment of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma.

Adam Olszewski, MD, debates that...

05/03/2023

Oncology

Videos

Choosing the Optimal Treatment for Patients With Newly Diagnosed Multiple Myeloma

05/03/2023

At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Peter M. Voorhees, MD, shared strategies for selecting a frontline therapy for patients with multiple myeloma.

At the 2023 Great Debates &...

05/03/2023

Oncology

Recent News

News

UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer

11/19/2024

Stephanie Holland ;

According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...

According to results from the...

11/19/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology